Which gram-negative bacteria are covered by ampicillin and what are the appropriate dosing recommendations?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 27, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ampicillin Gram-Negative Coverage

Ampicillin has limited gram-negative coverage, primarily effective against E. coli, Proteus mirabilis, H. influenzae, and some Salmonella/Shigella species, but resistance rates are high (40-60% for E. coli) and it lacks activity against Pseudomonas, Klebsiella, and most other Enterobacteriaceae.

Covered Gram-Negative Organisms

According to FDA labeling and clinical guidelines, ampicillin demonstrates activity against 1:

Reliably Covered:

  • Haemophilus influenzae (respiratory infections)
  • Proteus mirabilis (urinary tract infections, septicemia)
  • Neisseria meningitidis (meningitis)
  • Neisseria gonorrhoeae

Variable Coverage (High Resistance Rates):

  • Escherichia coli - Only 40-60% remain susceptible 2, 3
  • Salmonella species (including S. typhi)
  • Shigella species

NOT Covered:

  • Pseudomonas aeruginosa - inherently resistant 1
  • Klebsiella species - generally insensitive 4
  • Enterobacter species - generally insensitive 4
  • Acinetobacter baumannii - requires sulbactam component 5

Critical Resistance Considerations

The major limitation is beta-lactamase production. Ampicillin does NOT resist destruction by penicillinase 1. Historical data shows 80% E. coli susceptibility in 1967 4, but current resistance reaches 40-60% 2. Recent 2024 data confirms ampicillin/amoxicillin shows >55% resistance across all age groups for UTIs 3.

Clinical Dosing Recommendations

Adults 1:

  • Standard dose: 1-2 g IV every 4-6 hours
  • High-dose for enterococcal coverage: 18-30 g IV daily in divided doses 6
  • Meningitis: Higher doses required for CNS penetration

Pediatrics 7:

  • General infections: 50 mg/kg IV every 6 hours (QDS)
  • Meningitis: 50 mg/kg IV every 6 hours for 3 weeks
  • Sepsis (with gentamicin): 50 mg/kg IV every 6 hours

When to Use Ampicillin vs. Alternatives

Use ampicillin alone ONLY when:

  • Treating enterococcal infections (remains preferred anti-enterococcal agent) 2
  • Documented susceptibility confirmed by culture
  • Treating uncomplicated VRE cystitis (high-dose regimen) 6

Ampicillin-sulbactam is superior for:

  • Mixed aerobic/anaerobic infections 8, 9
  • Animal/human bite wounds 9, 10
  • Intra-abdominal infections 11
  • Carbapenem-resistant Acinetobacter (sulbactam provides the activity) 5, 12

Better alternatives for empiric gram-negative coverage:

  • Ceftriaxone/cefotaxime - broader gram-negative spectrum 13, 11
  • Fluoroquinolones - better E. coli coverage but reserve for specific indications 9
  • Piperacillin-tazobactam - broader coverage including Pseudomonas 11
  • Amoxicillin-clavulanate - overcomes beta-lactamase resistance 9, 11

Common Pitfalls

Do not use ampicillin monotherapy for:

  • Empiric treatment of hospital-acquired infections
  • Suspected Pseudomonas or Klebsiella infections
  • Community-acquired UTIs without culture confirmation (>55% resistance) 3
  • Pneumonia in patients with COPD (H. influenzae may be resistant) 13

Always add aminoglycoside when treating:

  • Gram-negative meningitis 1
  • Enterococcal endocarditis 14
  • Serious gram-negative sepsis 1

The combination of ampicillin with gentamicin provides synergy and broader coverage, addressing ampicillin's gram-negative limitations while maintaining enterococcal activity 7, 11.

References

Research

Aminopenicillins in urology.

Urology, 1992

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.